New drug cocktail targets Hard-to-Treat gut cancers

NCT ID NCT05039177

Completed Disease control Sponsor: Erasca, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new cancer drug called ERAS-007, given by mouth, together with other targeted therapies in 101 people with advanced colorectal or pancreatic cancers that have certain gene changes. The main goals were to check safety, find the best dose, and see how the drugs work in the body. The trial is now complete, and results will help guide future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ERAS-007 (a targeted cancer drug taken by mouth) combined with other drugs (encorafenib, cetuximab, or palbociclib)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced colorectal or pancreatic cancers that have specific genetic mutations.
What could go wrong: This is an early-phase trial focused on safety and dosing, not yet on effectiveness. The combination may cause side effects or fail to shrink tumors. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm digestive system neoplasm Digestive System Neoplasms pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Duke Cancer Institute

Durham, North Carolina, 27710, United States
Henry Ford Cancer Institute

Detroit, Michigan, 48202, United States
Massachusetts General Hospital

Boston, Massachusetts, 02215, United States
Sarah Cannon Research Institute (Tennessee Oncology)

Nashville, Tennessee, 37203, United States
Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States
The Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
UCSF Mount Zion Medical Ctr

San Francisco, California, 94158, United States
University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)

Birmingham, Alabama, 35233, United States
University of California Irvine College of Medicine

Orange, California, 92868, United States
University of Washington - Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States
Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States
Washington University (Siteman Cancer Center)

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.